To evaluate the role of TET2 in regulating KIR expression, we first analyzed the type and the positioning of the TET2 mutations found in MDS/CMML patients with a reduced percentage of KIR+ NK cells (below 25%) at diagnosis (Fig. 3a). Here, KIR3DL1 is linked to chronic myelomonocytic leukemia.